The site is undergoing maintenance. Ordering can continue through fax and phone.
If you encounter problems while ordering. Please contact us at BDBCustomerService@bd.com
See More
BD Horizon™ BV421 Mouse Anti-CXCR7
Clone 10D1 (RUO)
Flow cytometric analysis of CXCR7 expression on mouse leukocytes (Left Panel). C57BL/6 splenocytes were treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) and pre-incubated with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™, Cat. No. 553141 or 553142). To demonstrate the expression of CXCR7 on marginal-zone B lymphocytes, the splenocytes were co-stained with six fluorochrome-conjugated monoclonal antibodies in the BD Horizon™ Brilliant Stain Buffer (Cat. No. 563794/566349/566385): FITC Rat Anti-Mouse CD21/CD35 (Cat. No. 553818 or 561769), Alexa Fluor® 647 Rat Anti-Mouse CD9 (Cat. No. 564233), BD Horizon™ PE-CF594 Rat Anti-Mouse CD45R (Cat. No. 562290 or 562313), BD Horizon™ BUV737 Rat Anti-Mouse CD23 (Cat. No. 564436), BD Horizon™ BUV395 Rat Anti-Mouse IgM (Cat. No. 564025) and either BD Horizon™ BV421 Mouse Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439; dotted-line histograms). The histograms were derived from gated viable splenocytes expressing with the B220-positive, IgM-high, CD21-high, CD23-low, CD9-positive phenotype.
Flow cytometric analysis of CXCR7 expression on human CXCR7-transfected 293F cells (Middle and Right Panels). Untransfected 293F cells (Middle Panel) and 293F cells transfected with a human CXCR7 construct (Right Panel) were initially fixed with BD Cytofix Fixation Buffer (Cat. No. 554655) and then stained with either BD Horizon BV421 Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439, dotted-line histogram). The histograms were derived from gated events based on the light scattering characteristics of intact 293F cells.
Flow cytometry was performed on a BD LSRFortessa™ X-20 Cell Analyzer.
Flow cytometric analysis of CXCR7 expression on mouse leukocytes (Left Panel). C57BL/6 splenocytes were treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) and pre-incubated with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™, Cat. No. 553141 or 553142). To demonstrate the expression of CXCR7 on marginal-zone B lymphocytes, the splenocytes were co-stained with six fluorochrome-conjugated monoclonal antibodies in the BD Horizon™ Brilliant Stain Buffer (Cat. No. 563794/566349/566385): FITC Rat Anti-Mouse CD21/CD35 (Cat. No. 553818 or 561769), Alexa Fluor® 647 Rat Anti-Mouse CD9 (Cat. No. 564233), BD Horizon™ PE-CF594 Rat Anti-Mouse CD45R (Cat. No. 562290 or 562313), BD Horizon™ BUV737 Rat Anti-Mouse CD23 (Cat. No. 564436), BD Horizon™ BUV395 Rat Anti-Mouse IgM (Cat. No. 564025) and either BD Horizon™ BV421 Mouse Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439; dotted-line histograms). The histograms were derived from gated viable splenocytes expressing with the B220-positive, IgM-high, CD21-high, CD23-low, CD9-positive phenotype.
Flow cytometric analysis of CXCR7 expression on human CXCR7-transfected 293F cells (Middle and Right Panels). Untransfected 293F cells (Middle Panel) and 293F cells transfected with a human CXCR7 construct (Right Panel) were initially fixed with BD Cytofix Fixation Buffer (Cat. No. 554655) and then stained with either BD Horizon BV421 Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439, dotted-line histogram). The histograms were derived from gated events based on the light scattering characteristics of intact 293F cells.
Flow cytometry was performed on a BD LSRFortessa™ X-20 Cell Analyzer.
Flow cytometric analysis of CXCR7 expression on mouse leukocytes (Left Panel). C57BL/6 splenocytes were treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) and pre-incubated with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™, Cat. No. 553141 or 553142). To demonstrate the expression of CXCR7 on marginal-zone B lymphocytes, the splenocytes were co-stained with six fluorochrome-conjugated monoclonal antibodies in the BD Horizon™ Brilliant Stain Buffer (Cat. No. 563794/566349/566385): FITC Rat Anti-Mouse CD21/CD35 (Cat. No. 553818 or 561769), Alexa Fluor® 647 Rat Anti-Mouse CD9 (Cat. No. 564233), BD Horizon™ PE-CF594 Rat Anti-Mouse CD45R (Cat. No. 562290 or 562313), BD Horizon™ BUV737 Rat Anti-Mouse CD23 (Cat. No. 564436), BD Horizon™ BUV395 Rat Anti-Mouse IgM (Cat. No. 564025) and either BD Horizon™ BV421 Mouse Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439; dotted-line histograms). The histograms were derived from gated viable splenocytes expressing with the B220-positive, IgM-high, CD21-high, CD23-low, CD9-positive phenotype.
Flow cytometric analysis of CXCR7 expression on human CXCR7-transfected 293F cells (Middle and Right Panels). Untransfected 293F cells (Middle Panel) and 293F cells transfected with a human CXCR7 construct (Right Panel) were initially fixed with BD Cytofix Fixation Buffer (Cat. No. 554655) and then stained with either BD Horizon BV421 Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439, dotted-line histogram). The histograms were derived from gated events based on the light scattering characteristics of intact 293F cells.
Flow cytometry was performed on a BD LSRFortessa™ X-20 Cell Analyzer.
Flow cytometric analysis of CXCR7 expression on mouse leukocytes (Left Panel). C57BL/6 splenocytes were treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) and pre-incubated with Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™, Cat. No. 553141 or 553142). To demonstrate the expression of CXCR7 on marginal-zone B lymphocytes, the splenocytes were co-stained with six fluorochrome-conjugated monoclonal antibodies in the BD Horizon™ Brilliant Stain Buffer (Cat. No. 563794/566349/566385): FITC Rat Anti-Mouse CD21/CD35 (Cat. No. 553818 or 561769), Alexa Fluor® 647 Rat Anti-Mouse CD9 (Cat. No. 564233), BD Horizon™ PE-CF594 Rat Anti-Mouse CD45R (Cat. No. 562290 or 562313), BD Horizon™ BUV737 Rat Anti-Mouse CD23 (Cat. No. 564436), BD Horizon™ BUV395 Rat Anti-Mouse IgM (Cat. No. 564025) and either BD Horizon™ BV421 Mouse Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439; dotted-line histograms). The histograms were derived from gated viable splenocytes expressing with the B220-positive, IgM-high, CD21-high, CD23-low, CD9-positive phenotype.
Flow cytometric analysis of CXCR7 expression on human CXCR7-transfected 293F cells (Middle and Right Panels). Untransfected 293F cells (Middle Panel) and 293F cells transfected with a human CXCR7 construct (Right Panel) were initially fixed with BD Cytofix Fixation Buffer (Cat. No. 554655) and then stained with either BD Horizon BV421 Anti-CXCR7 (Cat. No. 566233 or 566234, solid-line histogram) or BD Horizon BV421 Mouse IgG2a, k Isotype Control (Cat. No. 562439, dotted-line histogram). The histograms were derived from gated events based on the light scattering characteristics of intact 293F cells.
Flow cytometry was performed on a BD LSRFortessa™ X-20 Cell Analyzer.
Product Details
BD Horizon™
ACKR3, CMKOR, RDC1, GPR159
Mouse (QC Testing), Human (Tested in Development)
Mouse C57BL/6 IgG2a, κ
Human CXCR7 Transfected Cell Line
Flow cytometry (Routinely Tested)
0.2 mg/ml
AB_2744473
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO
Preparation And Storage
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV421 under optimum conditions, and unconjugated antibody and free BD Horizon BV421 were removed.
Recommended Assay Procedures
For optimal and reproducible results, BD Horizon Brilliant™ Stain Buffer should be used anytime BD Horizon Brilliant™ dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Alexa Fluor® is a registered trademark of Molecular Probes, Inc., Eugene, OR.
- Pacific Blue™ is a trademark of Molecular Probes, Inc., Eugene, OR.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™) RUO
Size
0.1 mg
Cat No.
553141
Purified Rat Anti-Mouse CD16/CD32 (Mouse BD Fc Block™) RUO
Size
0.5 mg
Cat No.
553142
Stain Buffer (BSA) RUO
Size
500 ML
Cat No.
554657
Stain Buffer (FBS) RUO
Size
500 ML
Cat No.
554656
Brilliant Stain Buffer RUO
Size
100 Tests
Cat No.
563794
Brilliant Stain Buffer RUO
Size
1000 Tests
Cat No.
566349
566234 Rev. 2
Antibody Details
10D1
The 10D1 monoclonal antibody specifically binds to mouse and human C-X-C chemokine receptor type 7 (CXCR7), a G protein-coupled receptor that interacts with high affinity to SDF-1 (CXCL12) and with low affinity to CXCL11 (I-TAC). These chemokines also bind to CD184 (CXCR4) and CD183 (CXCR3), respectively, and induce functional processes such as calcium mobilization and cell migration. In contrast to CXCR4, CXCR7-dependent signaling outcomes are somewhat unclear and may vary with cell type. CXCR7 is involved in the alignment of marginal-zone B lymphocytes to the splenic marginal zone and also plays critical roles in embryogenesis and malignancies.
566234 Rev. 2
Format Details
BV421
The BD Horizon Brilliant Violet™ 421 (BV421) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye has an excitation maximum (Ex Max) of 407-nm and an emission maximum (Em Max) at 423-nm. Driven by BD innovation, BV421 is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 420-nm (e.g., a 431/28-nm or 450/50-nm bandpass filter). BV421 is an ideal alternative for V450 as it is approximately ten times brighter with less spillover into the BV510/V500 detector. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
BV421
407 nm
423 nm
566234 Rev.2
Citations & References
View product citations for antibody "566234" on CiteAb
Development References (4)
-
Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling.. Blood. 2009; 113(24):6085-93. (Biology). View Reference
-
Mackay CR. Development and Uses for Monoclonal Antibodies to Chemoattractant Receptors. Current Immunology Reviews. 2012; 8Available: http://www.ingentaconnect.com/content/ben/cir/2012/00000008/00000002/art00006 2016, January 16.
-
Puchert M, Engele J. The peculiarities of the SDF-1/CXCL12 system: in some cells, CXCR4 and CXCR7 sing solos, in others, they sing duets.. Cell Tissue Res. 2014; 355(2):239-53. (Biology). View Reference
-
Sierro F, Biben C, Martínez-Muñoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc Natl Acad Sci U S A. 2007; 104(37):14759-14764. (Biology). View Reference
566234 Rev. 2
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.